

# (12) International Application Status Report

**Received at International Bureau:** 01 November 2002 (01.11.2002)

**Information valid as of:** (..)

**Report generated on:** 02 August 2021 (02.08.2021)

**(10) Publication number:**

WO2003/024394

**(43) Publication date:**

27 March 2003 (27.03.2003)

**(26) Publication language:**

English (EN)

**(21) Application Number:**

PCT/US2002/029150

**(22) Filing Date:**

13 September 2002 (13.09.2002)

**(25) Filing language:**

English (EN)

**(31) Priority number(s):**

09/953,620 (US)

**(31) Priority date(s):**

17 September 2001 (17.09.2001)

**(31) Priority status:**

Priority document received (in compliance with PCT Rule 17.1)

**(51) International Patent Classification:**

A61K 31/203 (2006.01)

**(71) Applicant(s):**

PARKS, L., Dean [US/US]; 2420 Southeast 15th Street Ocala, FL 34471 (US) *(for all designated states)*

**(72) Inventor(s):**

PARKS, L., Dean; 2420 Southeast 15th Street Ocala, FL 34471 (US)

**(74) Agent(s):**

SILVERMAN, Melvin, K.; Suite 500 500 West Cypress Creek Road Fort Lauderdale, FL 33309 (US)

**(54) Title (EN):** METHOD OF TREATING BENIGN PROSTATIC HYPERPLASIA AND OTHER BEINGN PORSTATE CONDITIONS

**(54) Title (FR):** METHODE DE TRAITEMENT D'HYPERPLASIE PROSTATIQUE BENIGNE ET D'AUTRES PATHOLOGIES PROSTATIQUES BENIGNES

**(57) Abstract:**

**(EN):** Methods of treatment of benign prostatic hyperplasia and reduction of the level of the prostate specific antigen (PSA) of benign prostate conditions are disclosed. The treatment method includes an initial treatment of patients with orally administration of an initial dosage of about 40 mg 13 cis-retinoic acid daily for a period from about ten days to about twenty days, and followed by a sustaining treatment of the patients with orally administration of a sustaining dosage of about 40 mg 13 cis-retinoic acid about every five to seven days in a sustaining period.

**(FR):** L'invention concerne des méthodes de traitement d'hyperplasie prostatique bénigne et de réduction du niveau d'antigène spécifique de la prostate (PSA) dans des pathologies prostatiques bénignes. Ces méthodes de traitement comprennent un traitement initial des patients consistant à administrer par voie orale un dosage initial d'environ 40mg d'acide 13-cis rétinolique par jour, pendant une période d'environ dix à environ vingt jours, et suivi par un traitement prolongé des patients avec administration par voie orale d'environ 40 mg d'acide 13-cis rétinolique environ tous les cinq à sept jours pendant une période prolongée.

**International search report:**

Received at International Bureau: 14 March 2003 (14.03.2003) [US]

**International Report on Patentability (IPRP) Chapter II of the PCT:**

Chapter II demand received: 07 February 2003 (07.02.2003)

**(81) Designated States:**

AE, AT, AU, AZ, BG, BR, BY, BZ, CA, CH, CN, CR, CU, DE, EE, FI, GB, GE, HR, HU, ID, IL, IN, JP, KG, KR, KZ, LT, LV, MA, MD, MK, MX, MZ, NO, NZ, PL, PT, RO, RU, SE, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, YU, ZA

European Patent Office (EPO) : AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR

African Regional Intellectual Property Organization (ARIPO) : GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW

Eurasian Patent Organization (EAPO) : AM, AZ, BY, KG, KZ, MD, RU, TJ, TM